Alzheimer's Drugs Market Size and Forecast (2021 - 2031), Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Drug Class [Cholinesterase Inhibitors (Donepezil, Rivastigmine, and Galantamine) NMDA Receptor Antagonists, Co

The Alzheimer's drugs market size is expected to grow from US$ 8.24 billion in 2024 to US$ 26.37 billion by 2031; it is projected to register a CAGR of 13.6% during 2025-2031. The aging population & rising Alzheimer's prevalence, and improved diagnostics & early detection are noteworthy factors contributing to the expansion of the Alzheimer's drugs market size. However, the high cost of disease-modifying therapies hinders the Alzheimer's drugs market.

Public-private partnerships and funding leverage the resources of government organizations, academic centers, pharmaceutical firms, and philanthropic foundations to speed up the creation of effective treatments. The US National Institutes of Health (NIH)'s Accelerating Medicines Partnership-Alzheimer's Disease (AMP-AD 2.0) has attracted a substantial number of resources to drive research on Alzheimer's. This initiative integrates more than US$61 million of public investment from the NIH with investment from pharmaceutical firms like Eisai and Takeda. This project promotes open sharing of data and precision medicine strategies, accelerating biomarker discovery and validation of therapeutic targets. Philanthropic initiatives like BrightFocus and Part the Cloud have invested millions in early-stage research, backing forward-thinking projects which have secured more than a billion dollars in funding from multiple sources, ranging from venture capital to pharma partnerships. At the state level, the proposed Texas Dementia Prevention and Research Institute of Texas (DPRIT) would commit up to US$3 billion over ten years to dementia research, fostering collaborations that might spur local biotech expansion and clinical breakthroughs. Furthermore, partnerships among big pharma and biotechs are on the rise, such as with Biogen in partnership with Eisai to co-develop and market Alzheimer's therapies, pooling resources and capabilities to drive faster entry into markets. These public-private initiatives mitigate financial risks and enhance resource sharing, de-risking drug development, and compress timelines. Commercially, they diversify the Alzheimer's drugs pipeline, stimulate investment from biotech and pharma, and boost regulatory and public trust in new medicines. These partnerships and funding influxes are accelerating disease-modifying treatments and underpinning a more innovation-driven Alzheimer's drugs market.

End User-Based Insights

Based on end user, the Alzheimer's drugs market is segmented into hospital pharmacies, retail pharmacies, and online pharmacies. The hospital pharmacies segment held the largest Alzheimer's drugs market share in 2024. Particularly in areas where hospital-based care is the main method of diagnosis and treatment initiation, hospital pharmacies distribute and oversee AD medications. Hospital pharmacies are essential resources for prescribing, dispensing, and advising patients and caregivers on therapeutic options due to the complexity of managing Alzheimer's disease, which calls for specialized neurologists or geriatricians. The sale of Alzheimer's medications in hospital pharmacies is influenced by reimbursement regulations and changing treatment recommendations. Hospitals continue to prescribe ChEIs as the first-line symptomatic treatments for mild to moderate AD. Because of its demonstrated effectiveness and tolerability, donepezil (Aricept), the most prescribed ChEI worldwide, is included in hospital formularies. Rivastigmine provides the dosing flexibility preferred in hospital settings where patient monitoring is practical. It is available as oral capsules and transdermal patches. Hospital pharmacies add value by providing medication counseling, adherence monitoring, and managing side effects-services critical in Alzheimer's treatment. Such programs differentiate hospital pharmacy offerings from retail outlets and support patient outcomes, potentially driving demand for specific formulations (e.g., rivastigmine patches for better compliance), thereby fueling the Alzheimer's drugs market growth.

The World Health Organization and Medicare are among the primary and secondary sources referred to while preparing the Alzheimer's drugs market report.

Reasons to Buy

Save and reduce time carrying out entry-level research by identifying the growth, size, leading players and segments in the global Alzheimer's Drugs market.
Highlights key business priorities in order to assist companies to realign their business strategies
The key findings and recommendations highlight crucial progressive industry trends in the global Alzheimer's Drugs market, thereby allowing players across the value chain to develop effective long-term strategies
Develop/modify business expansion plans by using substantial growth offering developed and emerging markets
Scrutinize in-depth global market trends and outlook coupled with the factors driving the market, as well as those hindering it.
Enhance the decision-making process by understanding the strategies that underpin commercial interest with respect to client products, segmentation, pricing and distribution Show more